Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: A double-blind randomized clinical trial

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 115-124

  Carbonell, Josep L L ^a   Acosta, Rita ^b   Pérez, Yasmiriam ^b   Marrero, Ana G ^b   Trellez, Edilia ^b   Sánchez, Carlos ^b   Tomasi, Giuseppe ^c  

^a Mediterranea Medica Clinic   (Spain)

^b Eusebio Hernandez Gynecology and Obstetrics Teaching Hospital   (Cuba)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antiprogestins; Fibroid; Leiomyoma; Mifepristone

Indexed keywords

MIFEPRISTONE;

ADULT; AMENORRHEA AND OLIGOMENORRHEA; ARTICLE; BLEEDING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CUBA; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; FATIGUE; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MENORRHAGIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME; UTERUS MYOMA; VOMITING;

EID: 84875313312     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S33125     Document Type: Article

References (26)

1. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernéndez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112(5): 1029-1036.
2. Carbonell Esteve JL, Quiróz Rámirez GM, Borge A, Castellón Zapata LE, Aragón WC, Tomasi G. Mifepristona 5 mg frente a 10 mg diarios en el tratamiento del leiomioma. Ensayo clínico aleatorizado [Mifepristone 5 mg versus 10 mg daily in the treatment of leiomyoma. Randomized Trial]. Progresos de Obstetricia y Ginecología. 2010;53(2):51-58. Spanish
3. Carbonell JL, Acosta R, Pérez Y, Yero MC, Seigler I, Heredia B. Evolución del leiomioma uterino después del tratamiento con mifepristona. Ensayo clínico aleatorizado [Evolution of uterine leiomyoma after treatment with mifepristone: a randomized clinical trial]. Progresos de Obstetricia y Ginecología. 2010;53(6):231-236. Spanish
4. Carbonell Esteve JL, Acosta R, Heredia B, et al. Mifepristona para tratamiento del fibroma uterino [Mifepristone to treat uterine fibroids]. Revista Cubana de Obstetricia y Ginecología. 2010:36(2). Spanish
5. Esteve JL, Acosta R, Pérez Y, Campos R, Hernéndez AV, Texidó CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012;161(2): 202-208.
6. Carbonell Esteve JL, Riverón AM, Cano M, et al. Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery. Int J Womens Health. 2012;4:75-84.
7. Eisinger SH, Meldrum S, Ficella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2): 243-250.
8. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelvemonth safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12(3):227-233.
9. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006; 108(6):1381-1387.
10. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870-1879.
11. Yang Y, Zheng S, Li K, et al. Treatment of uterine leiomyoma by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi. 1996; 31(10):624-626. Chinese.
12. Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone. Zhonghua Fu Chan Ke Za Zhi. 1998;33(8):490-492.
13. Horn FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007; 13(6):567-580.
14. Mutter GL, Bergeron C Deligdisch, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591-598.
15. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99(2):290-300.
16. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynecol. 2009; 49(1):77-83.
17. Faul F. G*Power [computer program]. Version 3.0.10. Kiel: Universitat Kiel. Germany.
18. US Department of Health and Human Services, Food and Drug Administration, US Department of Health and Human Services, Center for Biologics Evaluation and Research. Guidance for Industry: Drug-Induced Liver Injury; Premarketing Clinical Evaluation. Silver Spring and Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, US Department of Health and Human Services, Center for Biologics Evaluation and Research; 2009. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf. Accessed November 12, 2012
19. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82(5):442-452.
20. Silverberg SG, Kurman RJ. Endometrial carcinoma. In: Atlas of Tumor Pathology: Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. Washington DC: Armed Forces Institutes of Pathology; 1991:47-89.
21. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Uterine corpus. In: Histological Typing of Female Genital Tract Tumors. 2nd ed. New York, NY: Springer-Verlag; 1994:13-31.
22. Mutter GL. EIN overview [web page on the Internet]. Harvard Medical School and Brigham Women's Hospital; nd. Available at: http://www.endometrium.org/EIN%20Central/FramePages/EINOverviewFrame%28ModuleI%29.htm. Accessed Jan 2008.
23. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect f long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18(1):61-68.
24. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab. 2002;87(1):63-70.
25. Spies JB, Warren EH, Mathias SD, Walsh SM, Roth AR, Pentecost MJ. Uterine fibroid embolization: measurement of health-related quality of life before and after therapy. J Vasc Interv Radiol. 1999;10(10): 1293-1303.
26. Fiscella F, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947-953.